Absolute Markets Insights offers its latest published report ‘Somatostatin Receptor Type 4 Market by Type (CNTX-0290, NNC-26910, Veldoreotide); by Application (Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer’s Disease, Cognitive Disorder, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor, Pituitary ACTH Hypersecretion); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis.  The author of the report analyzed that the global somatostatin receptor type 4 market accounted for US$ 941.2 Mn in 2017.

Since somatostatin was discovered as a growth hormone inhibitor, the inhibitory function along with other tissue functions is being reproduced through five different receptors including the receptor 4. These receptors can inhibit functions including angiogenesis, modulation of glucagon secretion, cell proliferation, peristalsis in the jejunum, insulin secretion and neuronal activity. In addition, new possibilities have opened up in tumor treatment and accompanying symptoms with the expression of somatostatin receptor 4 (SSTR4) on neuroendocrine tumor cells., Scintigraphic tumor imaging as well as intraoperative tumor localization can be performed after injection of a radiolabeled long-acting somatostatin receptor type 4 analog.

The growing demand for SSTR4 assays crosswise over different therapeutic areas has driven pharmaceutical organizations to collaborate for drug development. Additionally, rising use of somatostatin receptors in cancer diagnosis and treatment and advancement forms are relied upon to fuel the market. The demand for SSTR4 assays in multiple therapeutic areas including cardiovascular, respiratory and degenerative disorders; surge in government initiatives and demand for improved SSTR4 assays in drug discovery is aiding the somatostatin receptor type 4 market growth as well.

Purchase the complete report titled “Somatostatin Receptor Type 4 Market – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026” at https://www.absolutemarketsinsights.com/reports/Somatostatin-Receptor-Type-4-Market-2018-2026-121

Chronic Pain in the Application Segment Is Expected to Dominate the Somatostatin Receptor Type 4 Market

Individuals suffering from chronic, debilitating pain generally resort to the assortment of temporary pain treatment alternatives such as NSAIDs, hyaluronic acid, opioids and surgery. Somatostatin plays critical role in pain regulation. It is capable of inhibiting inflammation and nociceptive processes via the SSTR4 pathway even in cases where opioids fail. It also plays significant role in neuromodulations. CNTX-0290 is a drug target that operates by stimulating the SSTR4 receptor, has huge potential for development of an absolutely new class of pain therapeutics. It is capable of turning down the activity of several other pain receptors.

Asia Pacific to be Most Attractive Market in Terms of Revenue During the Forecast Period, 2018-2026

As Asia Pacific is witnessing numerous government initiatives and involvement of global key players, the region is anticipated to reach US$ 370.8 Mn by 2025. China recently conducted the 9th Annual China Healthcare Investment Conference (CHIC) on March 27-29, 2018 that highlighted the latest healthcare investment opportunities in light of China’s recent major policy reforms. One of the highlights was investment by global private players in drug development.  

Competitive Landscape

Key participants of global somatostatin receptor type 4 market are Centrexion Therapeutics, CRINETICS PHARMACEUTICALS and Strongbridge Biopharma plc amongst others.

Novartis received FDA approval for Lutathera (lutetium Lu 177 dotatate), a radiolabeled somatostatin analog, for the treatment of patients with somatostatin receptor–positive gastro-enteropancreatic tumors (GEP-NETs). The trial for approval compared Lutathera with high-dose octreotide LAR for patients with 1 or 2 metastatic midgut NETs.

Market By Type

• CNTX-0290
• NNC-26910
• Veldoreotide

Somatostatin Receptor Type 4 Market - By Application

• Chronic Pain
• Acromegaly
• Neuropathic Pain
• Alzheimer’s Disease
• Cognitive Disorder
• Dementia
• Diabetic Retinopathy
• Gastrointestinal Tumor
• Neuroendocrine Tumors
• Pancreatic Tumor
• Pituitary ACTH Hypersecretion

Market By Region

• North America
  • U.S.
  • Rest of North America
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific
• Middle East and Africa
  • GCC Countries
  • Southern Africa
  • Rest of Middle East and Africa
• Latin America
  • Brazil
  • Rest of Latin America